![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25814-25820, September 3, 1999
From the Here we describe the identification and
characterization of a novel mouse gene, PDCR, that encodes
a peroxisomal Mammalian peroxisomes contain multiple overlapping and
complementary fatty acid Recent studies have identified mammalian genes that encode the
peroxisomal Cloning and Sequencing the Mus musculus PDCR Gene--
All
sequence searches were performed using algorithms and data bases
available at the National Center for Biotechnology Information web
site. Mammalian homologues of the putative Caenorhabditis elegans peroxisomal Plasmids--
The Escherichia coli strain DH10B was
used for the maintenance and amplification of all plasmids (12). All
polymerase chain reactions were performed with a low error rate mixture
of polymerases (Expand; Roche Molecular Biochemicals). A full-length
form of the mouse PDCR open reading frame was generated by
polymerase chain reaction using the cDNA clone 1888282 as a
template and the oligonucleotides MmPDCR.5
(5'-GAAGTCGACCATGGCCCAGCCGCCGCCCGACGTTG-3') and MmPDCR.3
(5'-GAACGCGGCCGCGAATGCCTTTAATCCCAG-3') as primers. These
oligonucleotides append SalI and NotI sites
(underlined) at the 5' and 3' ends of the mouse PDCR open
reading frame, respectively. The product of this polymerase chain
reaction was digested with SalI and NotI and
subcloned into the corresponding sites of pT7-His6. pT7-His6 is a modified form of pET28A (Novagen, Inc.) that
contains XhoI and SalI sites in place of the
NheI-HindIII fragment found in the parental
vector. The sequence of the mouse PDCR open reading frame in
pT7-His6 was confirmed by automated fluorescent sequencing, and the resulting plasmid was denoted pT7-His6-PDCR. This
plasmid allows for T7-driven expression of a form of mouse PDCR bearing an N-terminal hexahistidinyl extension in the E. coli strain
BL21(DE3) (Novagen). To generate the N-terminal c-myc-tagged
form of the mouse PDCR open reading frame, the
SalI-NotI insert of pT7-His6-PDCR was
excised and subcloned into XhoI and NotI sites of
pcDNA3-Nmyc (13). This plasmid allows for constitutive
expression of an N-terminally c-myc-tagged form of mouse
PDCR in mammalian cells.
Purification of Enzymes--
The E. coli strain
BL21(DE3) was chosen for high level heterologous expression of the
His6-PDCR protein. Specifically, several colonies from a
plate of freshly transformed BL21(DE3) cells harboring the plasmid
pT7-His6-PDCR were used to inoculate a 50-ml preculture of
LB medium supplemented with 1% glucose and 25 µg/ml kanamycin sulfate. This preculture was grown 12 h at 30 °C with vigorous shaking (300 rpm), at which time 20 ml of the preculture were used to
inoculate 500 ml of 2YT medium supplemented with 25 µg/ml kanamycin
sulfate. This culture was grown with vigorous shaking for approximately
7 h at 18 °C until the A600 was
approximately 0.4, at which time induction of protein expression was
begun by the addition of
isopropyl-
The induced cells were resuspended in 50 ml of binding buffer (20 mM sodium-Pi (pH 7.8), 500 mM
sodium chloride, and 5 mM benzamidine HCl) with 5 mM 2-mercaptoethanol, and the cells were lysed by
sonication (14). Following cell lysis, a clarified extract was prepared
by centrifuging the sonicate at 25,000 × g for 30 min
at 4 °C. This extract (50 ml) was diluted to 150 ml with binding
buffer and was applied at 1.5 ml/min to a 2-ml bed of Chelating
Sepharose Fast Flow (Amersham Pharmacia Biotech) that was previously
charged with nickel (II) chloride and equilibrated in binding buffer at
18 °C. After the entire extract was applied, the resin was washed
sequentially with 50 bed volumes of binding buffer at pH 7.8 followed
by 50 bed volumes of binding buffer at pH 6.0.
An imidazole step gradient in binding buffer at pH 6.0 was chosen to
elute the bound proteins. Specifically, 2.5 column volumes of buffers
containing imidazole at 50, 250, 350, and 500 mM were applied sequentially to the resin, and the individual eluents were
collected. Proportional amounts of each fraction were analyzed by 15%
SDS-polyacrylamide gel electrophoresis for the presence and purity of
His6-PDCR (apparent Mr = 33,000).
Fractions containing highly purified His6-PDCR (>95%)
were removed, 2-mercaptoethanol was added to 5 mM final
concentration, and the protein in each fraction was precipitated for
storage by adding solid ammonium sulfate to 0.4 mg/ml. The purified,
precipitated protein was collected by centrifugation and stored under
buffer at
Analytical Methods and Substrate Synthesis--
All protein
determinations were done by the Bradford method (Bio-Rad) using bovine
serum albumin as a standard. Kinetic parameters (apparent
Vmax and Km) were obtained by
nonlinear curve fitting using the Sigma plot program. One unit of
enzyme activity is defined as the amount of enzyme that converts 1 µmol of substrate to product per min. The assay of
Cell Culture, Transfections, and Immunofluorescence--
Methods
for the culture and transfection of human skin fibroblasts have been
described (19). The normal human fibroblast cell line GM5756 was
purchased from the Coriell Cell Repository (Vineland, NJ). The
pex10-deficient Zellweger syndrome cell line, PBD100, has
been described (20). Methods for indirect immunofluorescence microscopy
were performed as described (19). Standard immunofluorescence conditions involved fixing the cells in 3.7%
formaldehyde/phosphate-buffered saline for 15 min and then
permeabilizing all cellular membranes in 1% Triton
X-100/phosphate-buffered saline for 5 min. For differential permeabilization experiments, the cells were fixed identically but
permeabilized with 25 µg/ml digitonin for 2 min only.
The tissue culture supernatant from mouse hybridoma line 1-9E10 (Roche
Molecular Biochemicals) was used as the source of the monoclonal
anti-c-myc antibody. Guinea pig polyclonal anti-PMP70 antibodies were raised against a synthetic peptide corresponding to the
C-terminal 18 amino acids of human PMP70 (21). Affinity purified,
polyclonal sheep antibodies recognizing human catalase were purchased
from The Binding Site (San Diego, CA) and were used according to the
manufacturer's suggestions. Affinity purified fluorescein anti-mouse
and anti-sheep and Texas Red anti-guinea pig secondary antibodies were
obtained from Kirkegaard and Perry Laboratories (Gaithersburg, MD) and
were used according to the manufacturer's suggestions.
Identification of a Murine Homologue of Saccharomyces cerevisiae
Sps19p--
Mammalian peroxisomes are capable of oxidizing unsaturated
fatty acids, and this process requires the enzymatic activity of
We attempted to identify the mammalian peroxisomal
Two murine ESTs encoded proteins that shared sequence similarity to the
N terminus of both F53C11.3 and yeast Sps19p and the corresponding
cDNA clones were obtained and characterized. Sequence analysis of
the longer PDCR cDNA clone revealed the presence of a
2048-base pair cDNA containing a 5'-untranslated region of 121 base
pairs, an 876-base pair open reading frame, and a 1451-base pair
3'-untranslated region (Fig. 2). The
sequence of the PDCR open reading frame was confirmed by sequencing the
second PDCR cDNA clone, which differed only in that it
had a slightly shorter 5'-untranslated region. The deduced product of
the PDCR gene is 292 amino acids long, has a predicted
molecular mass of 31,298 Da, and has a pI of 9.4. Like Sps19p and
F53C11.3, murine PDCR terminates in a match to the consensus type-1
peroxisomal targeting signal (26), Ala-Lys-Leu-COOH. Furthermore, an
amino acid alignment between mouse PDCR, C. elegans
F53C11.3, and S. cerevisiae Sps19p demonstrates that these
proteins share extensive sequence similarities across their lengths
(Fig. 3), with mouse PDCR showing 32 and 41% identity to the C. elegans and S. cerevisiae
proteins, respectively.
Mouse PDCR Encodes a
As a first assessment of the enzymatic activity of recombinant PDCR, we
employed a spectrophotometric method to monitor changes in the
absorbance spectrum of
It has previously been observed that the enzyme catalyzed reduction of
As a final test of PDCR activity, the chain length specificity of
purified PDCR was assessed with three substrates. The substrates chosen
for this study were
The PDCR Gene Encodes a Peroxisomal Protein--
The presence of a
consensus type-1 peroxisomal targeting signal (Ala-Lys-Leu-COOH) at the
C terminus of PDCR strongly suggested that this
The hypothesis that PDCR is a peroxisomal matrix protein predicts that
it should accumulate in the cytoplasm of cells that have a specific
defect in matrix protein import. Zellweger syndrome is a lethal human
disorder characterized by defects in peroxisomal matrix protein import
and is caused by defects in any of at least 12 different genes, all of
which play roles in peroxisome biogenesis. Previous studies have
established that the cell line PBD100, which was derived from a
Zellweger syndrome patient and has inactivating mutations in the
PEX10 gene, is unable to import peroxisomal matrix proteins
but has no apparent defect in the import of peroxisomal membrane
proteins (20). We transfected PBD100 cells with
pcDNA3-NmycPDCR and processed these cells for double
indirect immunofluorescence, again using antibodies specific for the
c-myc epitope tag and for PMP70 (Fig. 7, G and
H). The cytoplasmic accumulation of NmycPDCR in
these cells, even though they are able to import PMP70 into the
peroxisome membrane, supports the hypothesis that PDCR is a peroxisomal
matrix protein.
The work presented here describes the first molecular
characterization of a mammalian peroxisomal
Using immunofluorescence microscopy we observed that mouse PDCR is
targeted to the peroxisomal lumen. This experimental observation of
peroxisomal localization is consistent with several lines evidence presented here and elsewhere. First, the presence of the C-terminal sequence Ala-Lys-Leu-COOH in PDCR suggested that this enzyme would be
targeted efficiently to peroxisomes. This sequence represents a
consensus match to the type-1 peroxisomal targeting signal, an
obligatory C-terminal tripeptide motif that is present on the vast
majority of peroxisomal matrix proteins (32). Second, we observed a
distinct accumulation of PDCR in the cytoplasm of skin fibroblasts
derived from a PEX10-deficient Zellweger syndrome patient.
The molecular defects in these cells have been characterized at both
the genetic and protein level, and it is well established that these
cells are deficient in peroxisomal matrix protein import specifically
(20). Finally, it has been reported previously that a homotetrameric
Mammalian cells contain differentially compartmentalized pathways for
the These molecular studies of mouse peroxisomal
We thank Daniel Warren and Jacob Jones for
assistance with the immunofluorescence studies.
*
This work was supported by National Institutes of Health
Grants DK45787 and HD10981 (to S. J. G.) and by United States
Public Health Service Grants HL30847 from the NHLBI, National
Institutes of Health (to H. S.) and RR03060 to Research Centers of
Minority Institutions.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
2
R. J. A. Wanders, personal communication.
The abbreviations used are:
EST, expressed
sequence tag;
HPLC, high pressure liquid chromatography.
The Mouse Gene PDCR Encodes a Peroxisomal
2,
4-Dienoyl-CoA Reductase*
§,
,
Department of Biological Chemistry, The
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 and the ¶ Department of Chemistry, City College, City University
of New York, New York, New York 10031
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2,
4-dienoyl-CoA reductase.
The mouse PDCR cDNA contains an 892-base pair open
reading frame and is predicted to encode a 292-amino acid protein with
a deduced molecular mass of 31,298 Da that terminates in a consensus
type-1 peroxisomal targeting signal. Purified recombinant PDCR protein
was generated from Escherichia coli and catalyzed the
NADPH-dependent reduction of
2-trans,
4-trans-decadienoyl-CoA
with a specific activity of 20 units/mg. Enzymatic characterization
followed by high pressure liquid chromatography analysis of the
products revealed that PDCR converted
2-trans,
4-trans-decadienoyl-CoA
to a
3-enoyl-CoA but not to a
2-enoyl-CoA. Kinetic analyses demonstrated that PDCR is
active on a broad range of
2,
4-dienoyl-CoAs. Although the observed
substrate preference was to
2-trans,
4-trans-decadienoyl-CoA,
PDCR was also active on a C22 substrate with multiple
unsaturations, a result consistent with the role of peroxisomes in the
oxidation of complex, very long chain, polyunsaturated fatty acids. The
presence of a type-1 peroxisomal targeting signal Ala-Lys-Leu-COOH at
the C terminus of PDCR suggested that this protein may be peroxisomal.
We observed that tagged PDCR was efficiently transported to the
peroxisome lumen in normal human fibroblasts but not in cells derived
from a Zellweger syndrome patient with a specific defect in peroxisomal
matrix protein import. We conclude that this protein resides within the
peroxisome matrix and therefore represents the first mammalian
peroxisomal
2,
4-dienoyl-CoA reductase to
be characterized at the molecular level.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-oxidation pathways that are able to
metabolize a variety of different substrates, including saturated long
and very long chain fatty acids, branched chain fatty acids, and
dicarboxylic fatty acids. In addition, peroxisomes are able to degrade
a variety of unsaturated fatty acids and thus must contain auxiliary
enzymes such as
3,
2-enoyl-CoA isomerase,
3,5,
2,4-dienoyl-CoA isomerase, and
2,
4-dienoyl-CoA reductase (1). The
oxidation of fatty acids with an unsaturation at an even positioned
carbon eventually leads to formation of a
2,
4-dienoyl-CoA, which cannot be oxidized
by
-oxidation. Instead, the further oxidation of
2,
4-dienoyl-CoAs requires the successive
action of
2,
4-dienoyl-CoA reductase to
generate a
3-enoyl-CoA, and
3,
2-enoyl-CoA isomerase to convert this
intermediate to a
2-enoyl-CoA that can re-enter the
-oxidation spiral (see Fig. 1) (2). The oxidation of fatty acids
with pre-existing unsaturations at odd-positioned carbons would
appear to be even simpler, with one round of
-oxidation converting
the
2,
5-dienoyl-CoA to a
3-enoyl-CoA and
3,
2-enoyl-CoA isomerase converting this
to a
2-enoyl-CoA substrate for further oxidation (see
Fig. 1) (3). However, studies have established that there also exists a
2,
4-dienoyl-CoA
reductase-dependent pathway for returning
2,
5-dienoyl-CoAs to the core spiral (Fig.
1) (4, 5). Thus,
2,
4-dienoyl-CoA reductases appear to play
important roles in the oxidation of virtually all unsaturated fatty
acids.

View larger version (25K):
[in a new window]
Fig. 1.
Enzymatic steps specific for unsaturated
fatty acid metabolism.
-Oxidation of unsaturated fatty acids
with double bonds at even-numbered carbons yields
2,
4-dienoyl-CoAs, which are metabolized
as shown at left (2).
2,
5-Dienoyl-CoAs arising from
-oxidation of unsaturated fatty acids with double bonds extending
from odd-numbered carbons can return to the core spiral through both
hydratase/isomerase-pathway (center) (3) and the
reductase-dependent (right) shunt (4). Note that
2,
4-dienoyl-CoA reductase-catalyzed
reactions are involved in the metabolism of both dienoyl-CoA
species.
3,
2-enoyl-CoA isomerase (6)
and
3,5,
2,4-dienoyl-CoA isomerase (7),
but the structural basis for peroxisomal
2,
4-dienoyl-CoA reductase remains to be
determined. However, genes encoding mammalian mitochondrial
2,
4-dienoyl-CoA reductases have been
identified in both rat and humans (8, 9), and it is formally possible
that the peroxisomal reductase mRNA could be generated from the
same gene as the mitochondrial enzyme. In fact, such a mechanism is
used to generate both peroxisomal and mitochondrial forms of
3,5,
2,4-dienoyl-CoA isomerase (7).
Nonetheless, another possibility is that the peroxisomal
2,
4-dienoyl-CoA reductase is encoded by a
distinct gene that has yet to be recognized. Here we report the
identification and characterization of a novel mouse gene,
PDCR, and show that it encodes a peroxisomal
2,
4-dienoyl-CoA reductase.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2,
4-dienoyl-CoA
reductase (F53C11.3) were identified by TBLASTN searches of the human
and mouse expressed sequence tag data bases. Two cDNA clones from
the IMAGE consortium (1924380 and 1888282) corresponded to the mouse
ESTs1 AI316477 and AI286384
(GenBankTM accession numbers) and appeared to contain the
full-length open reading frame of murine PDCR cDNAs.
This was determined by the ability of these ESTs to encode proteins
that (i) shared significant sequence similarities over the N terminus
of F53C11.3 and yeast Sps19p and (ii) contained an appropriately
positioned ATG codon with a good match to the Kozak consensus for high
efficiency translation initiation (10, 11). These two clones were
obtained from Genome Systems (St. Louis, MO), and the clone with the
longer 5'-untranslated region (1924380) was sequenced in its entirety
on both strands. Amino acid sequence alignments were performed with
DNASTAR MegAlign software (Madison, WI) using the PAM250 substitution matrix.
-D-galactothiopyranoside to a final concentration of 1 mM. The induced culture was grown for an
additional 18 h under the same conditions. The induced cells were
harvested at 5,000 × g for 10 min at 4 °C at the
end of this period.
70 °C until needed.
2-Enoyl-CoA hydratase (crotonase) from bovine liver (15)
and
3,
2-enoyl-CoA isomerase from rat
liver mitochondria (16) were purified as described.
2,
4-dienoyl-CoA reductase was based on
the substrate-dependent oxidation of NADPH as described by
Kunau and Dommes (2). Acyl-CoA thioesters were analyzed or purified by
reverse-phase HPLC on a Waters µBondapak C18 column (30 cm × 3.9 mm) attached to a Waters gradient HPLC system. The
absorbance of the effluent was monitored at 254 nm. Separation of
different acyl-CoA thioesters was achieved by linearly increasing the
acetonitrile/H2O (9:1 v/v) content of the 50 mM ammonium-Pi buffer (pH 5.5) from 20 to 50% at a flow rate
of 2 ml/min.
2-trans,
4-trans-decadienoyl-CoA
(17),
2-trans,
4-trans-hexadienoyl-CoA
(18), and
2-trans,
4,
7,
10,
13,
16,
19-cis-docosaheptaenoyl-CoA
(18) were prepared as described.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2,
4-dienoyl-CoA reductase. Although this
activity has been detected in purified peroxisomes from mammalian
sources (22-24), the purification of this enzyme has proved difficult
and has limited detailed mechanistic and molecular studies of mammalian
peroxisomal
-oxidation. To understand the structural basis for
mammalian peroxisomal
2,
4-dienoyl-CoA
reductase activity and to provide material for mechanistic studies of
this enzyme, we initiated a computer-based search for genes that might
encode such an enzyme.
2,
4-dienoyl-CoA reductase gene by
searching for mammalian genes that were capable of encoding proteins
with significant sequence similarity to yeast peroxisomal
2,
4-dienoyl-CoA reductase, Sps19p (25).
However, our searches using the Sps19p sequence as a BLAST query
versus the data base of expressed sequence tags identified
only ESTs corresponding to the previously identified mammalian
mitochondrial
2,
4-dienoyl-CoA reductase
gene. Therefore, we altered our search strategy and restricted our
search to the recently completed C. elegans genome sequence.
Three putative
2,
4-dienoyl-CoA reductase
genes were identified in C. elegans, and the sequences of
their deduced products (C. elegans proteins T05C12.3, W01C9.4, and F53C11.3) were examined. These three proteins were all
highly similar to Sps19p, with BLAST e values of
e
27 to e
28. However,
one of these, F53C11.3, contained a match to the consensus type-1
peroxisomal targeting signal, Ser-Lys-Leu-COOH (26), at its C terminus.
The presence of the type-1 peroxisomal targeting signal indicated that
F53C11.3 might represent the peroxisomal
2,
4-dienoyl-CoA reductase of C. elegans, and we used the F53C11.3 sequence to rescan the data
bases of human and murine expressed sequence tags. Once again, the
majority of ESTs we identified corresponded to the previously
characterized mammalian mitochondrial
2,
4-dienoyl-CoA reductases. However, we
also identified expressed sequence tags representing a second gene (a
gene we have designated PDCR) that also shared significant
similarity to F53C11.3.

View larger version (79K):
[in a new window]
Fig. 2.
Identification of a murine homologue of
S. cerevisiae Sps19p. The nucleotide sequence of
the murine PDCR cDNA is shown along with the deduced
translation of the 876-base pair open reading frame contained therein.
The deduced PDCR protein is basic (pI = 9.4), has a predicted
subunit weight of 31,298, and terminates in the nearly consensus type-1
peroxisomal targeting signal Ala-Lys-Leu-COOH
(underlined).

View larger version (58K):
[in a new window]
Fig. 3.
Amino acid alignment of mouse PDCR with
putative C. elegans and S. cerevisiae homologues. Clustal amino acid alignment of mouse PDCR with
the hypothetical C. elegans protein F53C11.3 and S. cerevisiae Sps19p is shown. Residues that are conserved in all
three sequences are shown as white letters on a black
background.
2,
4-Dienoyl-CoA
Reductase--
To test the hypothesis that mouse PDCR
encoded a protein with
2,
4-dienoyl-CoA
reductase activity, we subcloned the entire mouse PDCR open
reading frame into the prokaryotic expression vector pT7-His6, expressed the His6-PDCR protein in
E. coli, and purified the soluble, recombinant enzyme by
immobilized metal ion affinity chromatography (Fig.
4). Analysis of the purified protein by
SDS-polyacrylamide gel electrophoresis demonstrated that the protein
was greater than 95% pure.

View larger version (43K):
[in a new window]
Fig. 4.
Purification of soluble, recombinant
His6-PDCR by immobilized metal ion affinity
chromatography. Hexahistidinyl-tagged PDCR was expressed and
purified from E. coli by immobilized metal ion affinity
chromatography. Chromatography was carried out as described under
"Experimental Procedures," and proportional amounts of the
following samples were analyzed by 15% SDS-polyacrylamide gel
electrophoresis: M, molecular mass markers (indicated);
L, clarified cell lysate; W, pH 7.8 and pH 6.0 column washes (combined); 50, 250,
350, and 500, imidazole concentration (in
mM) in step gradient column eluents. The position of
His6-PDCR is shown.
2-trans,
4-trans-decadienoyl-CoA
following the addition of PDCR (Fig. 5). The characteristic spectrum of a
2,
4-dienoyl-CoA is shown in Fig. 5,
spectrum 1, with major absorbance bands centered near 260 and 300 nm
that are attributable to the coenzyme A and dienoyl thioester moieties,
respectively. Addition of purified PDCR to the assay mixture resulted
in the disappearance of the dienoyl thioester chromophore at 300 nm and
a decrease in absorbance at 340 nm that reflects the oxidation of NADPH
(Fig. 5, spectra 2-4). This result demonstrated that
recombinant, purified mouse PDCR has intrinsic
2,
4-dienoyl-CoA reductase activity.

View larger version (15K):
[in a new window]
Fig. 5.
Mouse PDCR is a
2,
4-dienoyl-CoA
reductase. Spectral changes associated with the reduction of
2-trans,
4-trans-decadienoyl-CoA
by NADPH in the presence of purified PDCR. Spectrum 1,
2-trans,
4-trans-decadienoyl-CoA
(15 µM in 60 mM potassium-Pi (pH
7.4), 0.1 mM NADPH). The reference sample contained 60 mM potassium-Pi (pH 7.4) with 0.1 mM NADPH. Spectra 2-4, 5 s, 30 s, and
1 min after starting the reaction by the addition of purified PDCR
(0.44 µg/ml) to the reaction sample.
2-trans,
4-trans-dienoyl-CoAs
can result in either
3-enoyl-CoAs (25, 27, 28) or
2-enoyl-CoAs (27, 29). Thus, the PDCR-catalyzed
reduction of
2-trans,
4-trans-decadienoyl-CoA
shown in Fig. 5 was expected to yield either
3-decenoyl-CoA, as observed for bovine and yeast
reductases, or
2-decenoyl-CoA, as formed by the E. coli enzyme. To address the stereochemistry of the PDCR catalyzed
reaction directly, the reduction product of
2-trans,
4-trans-decadienoyl-CoA
was further characterized enzymatically, and the resulting products
were analyzed by HPLC (Fig. 6). As expected, the substrate
2-trans,
4-trans-decadienoyl-CoA
gave rise to a single peak on HPLC (Fig. 6A). Following
addition of both purified PDCR and NADPH, a second peak was detected
and was assigned to
3-decenoyl-CoA because this compound
did not serve as a substrate for purified crotonase
(
2-enoyl-CoA hydratase) (Fig. 6B). However,
when purified
3,
2-enoyl-CoA isomerase was
added to the reaction mixture, a third compound, presumably
2-decenoyl-CoA, was detected (Fig. 6C). This
assignment was verified by the conversion of the putative
2-decenoyl-CoA to 3-hydroxydecanoyl-CoA in the presence
of crotonase (Fig. 6D). Thus, the PDCR-catalyzed reduction
of
2-trans,
4-trans-decadienoyl-CoAs
gives rise to
3-enoyl-CoAs as previously observed for
other eukaryotic
2,
4-dienoyl-CoA
reductases (25, 27, 28).

View larger version (27K):
[in a new window]
Fig. 6.
HPLC analysis of the PDCR-catalyzed reaction
product. A, HPLC-purified
2-trans,
4-trans-decadienoyl-CoA
(8 nmol in 0.2 ml of 60 mM potassium-Pi (pH
7.4)). B, 8 nmol of
2-trans,
4-trans-decadienoyl-CoA
in 0.2 ml of 60 mM potassium-Pi (pH 7.4) after
incubation for 30 s with 0.1 mM NADPH and 0.2 µg of
mouse PDCR in the absence or in the presence of 0.1 unit of crotonase
from bovine liver. C, 12 nmol of
2-trans,
4-trans-decadienoyl-CoA
in 0.2 ml of 60 mM potassium-Pi (pH 7.4) after
incubation for 30 s with 0.1 mM NADPH, 0.13 µg of
rat liver
3,
2-enoyl-CoA isomerase, and
0.2 µg of mouse PDCR. D, the mixture contained 0.1 unit of
bovine liver crotonase in addition to the components listed for
C.
2,4,
2-trans,
4-trans-decadienoyl-CoA;
3,
3-decenoyl-CoA;
2,
2-decenoyl-CoA; 3HO,
3-hydroxydecanoyl-CoA.
2-trans,
4-trans-hexadienoyl-CoA,
2-trans,
4-trans-decadienoyl-CoA,
and
2-trans,
4,
7,
10,
13,
16,
19-cis-docosaheptaenoyl-CoA.
The apparent Km and Vmax
values for
2-trans,
4-trans-decadienoyl-CoA,
the best of the three substrates, were determined to be 6 µM and 20 units/mg, respectively (Table
I). This Km value is
similar to the value of 6.7 µM reported for the same
substrate with the bovine reductase (27), whereas the
Vmax of 20 units/mg is significantly higher than
the value of 3.9 units/mg reported for the bovine enzyme (27). We
observed that PDCR was active with substrates having acyl chains of 6 and 22 carbon atoms as well. However, the activities of PDCR toward these
2,
4-dienoyl-CoAs were markedly
lower, and the Km values were much higher than the
corresponding values obtained with
2-trans,
4-trans-decadienoyl-CoA
as the substrate.
Kinetic parameters of recombinant mouse
2,
4-dienoyl-CoA reductase
2,
4-dienoyl-CoA reductase was in fact a
peroxisomal enzyme. To determine whether PDCR was located within
peroxisomes, we modified the PDCR cDNA so that it
encoded the 10 amino acid c-myc epitope tag at its N
terminus and placed it downstream of the cytomegalovirus promoter in
the mammalian expression vector pcDNA3. The resulting plasmid,
pcDNA3-NmycPDCR, was transfected into human skin
fibroblasts. Three days later, the transfected cells were processed for
double indirect immunofluorescence microscopy using antibodies specific for the c-myc epitope tag, and for the cytoplasmically
exposed C-terminal tail of PMP70, an integral peroxisomal membrane
protein (30). Following permeabilization of all cellular compartments, we observed that NmycPDCR colocalized with PMP70 to
discrete, punctate structures characteristic of peroxisomes (Fig.
7, A and B). To
determine whether NmycPDCR was transported into the
peroxisome lumen, we repeated these experiments under differential
permeabilization conditions that allow detection of proteins on the
outer surface of peroxisome but not in the peroxisome lumen (Fig. 7,
C and D) (31). The inability to detect
NmycPDCR under these conditions suggested that the protein
was inside the peroxisome membrane, whereas the detection of cytosolic
tail of PMP70 confirmed that the antibodies did detect cytoplasmically
exposed antigens. Similar results were observed for the prototypic
peroxisomal enzyme marker, catalase, thereby reaffirming the validity
of the differential permeabilization protocol (Fig. 7, E and
F).

View larger version (84K):
[in a new window]
Fig. 7.
PDCR is a peroxisomal matrix protein.
Human skin fibroblasts expressing the Nmyc-PDCR cDNA
were processed for double indirect immunofluorescence after
permeabilization with 1% Triton X-100. The subcellular distribution of
Nmyc-PDCR was examined using anti-myc
(A) and anti-PMP70 (B) antibodies. Additional
Nmyc-PDCR expressing cells were permeabilized with 25 µg/ml digitonin and were stained with anti-myc
(C) and anti-PMP70 (D) antibodies. Cells
permeabilized with 25 µg/ml digitonin were also stained with
anti-catalase (E) and anti-PMP70 (F) antibodies.
Double indirect immunofluorescence was used to examine the distribution
of Nmyc-PDCR in pex10-deficient PBD100 cells
(permeabilized with 1% Triton X-100) and again with
anti-myc (G) and anti-PMP70 (H)
antibodies. Bar, 25 µm.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2,
4-dienoyl-CoA reductase. The mouse
cDNA encoding this enzyme (PDCR) was identified on the basis of its
potential to encode a protein highly similar to S. cerevisiae Sps19p. Enzymatic characterization of PDCR demonstrated
that this enzyme has significant, intrinsic
2,
4-dienoyl-CoA reductase activity and
that the product of its action on
2-trans,
4-trans-decadienoyl-CoA
was
3-decenoyl-CoA. Thus the catalytic mechanism of PDCR
can be assumed to be analogous to other eukaryotic
2,
4-dienoyl-CoA reductases, which have
previously been shown to reduce
2,
4-dienoyl-CoAs to
3-enoyl-CoAs (25, 27, 28). We observed that mouse PDCR
displays a substrate preference for
2-trans,
4-trans-decadienoyl-CoA
over both
2-trans,
4-trans-hexadienoyl-CoA
and
2-trans,
4,
7,
10,
13,
16,
19-cis-docosaheptaenoyl-CoA
based on the ratio of the observed Vmax and
Km constants for these substrates. The observed
preference for
2-trans,
4-trans-decadienoyl-CoA
likely reflects the cellular role of PDCR in peroxisomal
-oxidation,
namely in the oxidation of long and very long chain fatty acids
that contain unsaturations near the middle of the acyl chain (1).
Furthermore the observed activity of PDCR on
2-trans,
4,
7,
10,
13,
16,
19-cis-docosaheptaenoyl-CoA
is consistent with the established role of peroxisomes in the
metabolism of complex, very long chain, polyunsaturated fatty
acids such as arachidonic acid and prostaglandins (1).
2,
4-dienoyl-CoA reductase isolated from
rat liver peroxisomes has a subunit molecular mass of approximately
33,000 Da (24). Based on the deduced protein sequence of PDCR, the
calculated molecular mass of this novel enzyme is predicted to be
31,298 Da. Thus, the subunit mass of mouse PDCR is in good agreement
with that of an orthologous enzyme isolated from peroxisomes of a
highly related species.
-oxidation of fatty acids and the chemical details of the
individual steps in both mitochondrial and peroxisomal pathways appear
highly similar. For example, both systems require the action of the
auxiliary enzymes shown in Fig. 1 to completely oxidize unsaturated
fatty acids. Although the enzymatic steps involved in metabolizing
2,
4-dienoyl-CoA intermediates are
relatively well understood, the presence of two distinct shunts for
degrading
2,
5-dienoyl-CoAs raises
questions as to which pathway is responsible for the main flux of
carbon skeletons arising from such intermediates. Recent studies on the
mitochondrial metabolism of
2-trans,
5-cis-octenoyl-CoA
suggest that the hydratase/isomerase shunt handles a majority of the
metabolic flux for these intermediates (33). A corollary to this
finding is that the reductase-dependent pathway is
responsible for maintaining coenzyme A homeostasis in the presence of
the unavoidable and possibly deleterious action of
3,
2-enoyl-CoA isomerase on
2,
5-dienoyl-CoAs (Fig. 1) (33). Currently
there is no report in the literature that addresses questions of
metabolic flux for peroxisomal
2,
5-dienoyl-CoAs. Thus, an assessment of
these issues is needed to elaborate our general understanding of
peroxisomal unsaturated fatty acid metabolism.
2,
4-dienoyl-CoA reductase complete the
preliminary characterization of the known auxiliary enzymes of
mammalian peroxisomal
-oxidation. The significance of these studies
is underscored by the well established observation that defects in
peroxisomal fatty acid metabolism are directly linked to lethal
inherited human disorders (34). As of this report four genetically
distinct complementation groups of these peroxisomal disorders have
been described (34). Although two complementation groups are
attributable to defects in acyl-CoA oxidase and the
D-specific multifunctional enzyme, the precise enzymatic
deficiency in the remaining complementation groups is unknown.2 Because
2,
4-dienoyl-CoA reductase activity is
required for complete oxidation of all
2,
4-dienoyl-CoAs, as well as a portion of
2,
5-dienoyl-CoAs, the human form of
PDCR represents a candidate disease gene for these
disorders. In addition to these uncharacterized complementation groups
of peroxisomal fatty acid oxidation deficiency, there also exist
reports of a lethal human deficiency in
2,
4-dienoyl-CoA reductase (35, 36).
Interestingly, the molecular basis of this deficiency has yet to be
resolved. Although one group suggested that the defect lies in a
mitochondrial
2,
4-dienoyl-CoA reductase
(35), no report describing patient mutations in a gene encoding a
mitochondrial
2,
4-dienoyl-CoA reductase
exists in the literature, and the possibility that this deficiency is
peroxisome-associated has not been examined.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Dept. of
Biological Chemistry, The Johns Hopkins University School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205. Tel.: 410-955-3085; Fax: 410-955-0215; E-mail: stephen.Gould@qmail.bs.jhu.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kunau, W.-H.,
Dommes, V.,
and Schulz, H.
(1995)
Prog. Lipid Res.
34,
267-342[CrossRef][Medline]
[Order article via Infotrieve]
2.
Kunau, W.-H.,
and Dommes, P.
(1978)
Eur. J. Biochem.
91,
533-544[Medline]
[Order article via Infotrieve]
3.
Stoffel, W.,
and Caesar, H.
(1965)
Hoppe-Seyler's Z. Physiol. Chem.
341,
76-83[Medline]
[Order article via Infotrieve]
4.
Smeland, T. E.,
Nada, M.,
Cuebas, D.,
and Schulz, H.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6673-6677 5.
He, X.-Y.,
Shoukry, K.,
Chu, C.,
Yang, J.,
Sprecher, H.,
and Schulz, H.
(1995)
Biochem. Biophys. Res. Comm.
215,
15-22[CrossRef][Medline]
[Order article via Infotrieve]
6.
Palosaari, P. M.,
and Hiltunen, J. K.
(1990)
J. Biol. Chem.
265,
2446-2449 7.
Filppula, S. A.,
Yagi, A. I.,
Kilpelainen, S. H.,
Novikov, D.,
Fitzpatrick, D. R.,
Vihinen, M.,
Valle, D.,
and Hiltunen, J. K.
(1998)
J. Biol. Chem.
273,
349-355 8.
Hirose, A.,
Kamijo, K.,
Osumi, T.,
Hashimoto, T.,
and Mizugaki, M.
(1990)
Biochim. Biophys. Acta
1049,
346-349[Medline]
[Order article via Infotrieve]
9.
Koivuranta, K. T.,
Hakkola, E. H.,
and Hiltunen, J. K.
(1994)
Biochem. J.
304,
787-792
10.
Kozak, M.
(1989)
J. Cell Biol.
108,
229-241 11.
Kozak, M.
(1992)
Annu. Rev. Cell Biol.
8,
197-225[CrossRef]
12.
Grant, S. G.,
Jessee, J.,
Bloom, F. R.,
and Hanahan, D.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4645-4649 13.
Jones, J. M.,
Nau, K.,
Geraghty, M. T.,
Erdmann, R.,
and Gould, S. J.
(1999)
J. Biol. Chem.
274,
9216-9223 14.
Geisbrecht, B. V.,
Zhu, D.,
Schulz, K.,
Nau, K.,
Morrell, J. C.,
Geraghty, M.,
Schulz, H.,
Erdmann, R.,
and Gould, S. J.
(1998)
J. Biol. Chem.
273,
33184-33191 15.
Steinman, H.,
and Hill, R. L.
(1975)
Methods Enzymol.
35,
136-151[Medline]
[Order article via Infotrieve]
16.
Palosaari, P. M.,
Kilponen, J. M.,
Sormunen, R. T.,
Hassinen, I. E.,
and Hiltunen, J. K.
(1990)
J. Biol. Chem.
265,
3347-3353 17.
Cuebas, D.,
and Schulz, H.
(1982)
J. Biol. Chem.
257,
14140-14144 18.
Luo, M. J.,
He, X.-Y.,
Sprecher, H.,
and Schulz, H.
(1993)
Arch. Biochem. Biophys.
304,
266-271[CrossRef][Medline]
[Order article via Infotrieve]
19.
Slawecki, M.,
Dodt, G.,
Steinberg, S.,
Moser, A. B.,
Moser, H. W.,
and Gould, S. J.
(1995)
J. Cell Sci.
108,
1817-1829[Abstract]
20.
Warren, D. S.,
Morrell, J. C.,
Moser, H. W.,
Valle, D.,
and Gould, S. J.
(1998)
Am. J. Hum. Genet.
63,
347-359[CrossRef][Medline]
[Order article via Infotrieve]
21.
Gärtner, J.,
Moser, H.,
and Valle, D.
(1992)
Nat. Genet.
1,
16-23[CrossRef][Medline]
[Order article via Infotrieve]
22.
Hiltunen, J. K.,
Karki, T.,
Hassinen, I. E.,
and Osmundsen, H.
(1986)
J. Biol. Chem.
261,
16484-16493 23.
Dommes, V.,
Baumgart, C.,
and Kunau, W.-H.
(1981)
J. Biol. Chem.
256,
8259-8262 24.
Kimura, C.,
Kondo, A.,
Koeda, N.,
Yamanaka, H.,
and Mizugaki, M.
(1984)
J. Biochem.
96,
1463-1469 25.
Gurvitz, A.,
Rottensteiner, H.,
Kilpelainen, S. H.,
Hartig, A.,
Hiltunen, J. K.,
Binder, M.,
Dawes, I. W.,
and Hamilton, B.
(1997)
J. Biol. Chem.
272,
22140-22147 26.
Gould, S. J.,
Keller, G. A.,
Hosken, N.,
Wilkinson, J.,
and Subramani, S.
(1989)
J. Cell Biol.
108,
1657-1664 27.
Dommes, V.,
and Kunau, W.-H.
(1984)
J. Biol. Chem.
259,
1781-1788 28.
Mizugaki, M.,
Kimura, C.,
Kondo, A.,
Kawaguchi, A.,
Okuda, S.,
and Yamanaka, H.
(1984)
J. Biochem. (Tokyo)
95,
311-317 29.
Mizugaki, M.,
Kimura, C.,
Nishimaki, T.,
Yamamoto, H.,
Sagi, M.,
Nishimura, S.,
and Yamanaka, H.
(1982)
J. Biochem. (Tokyo)
92,
1671-1674 30.
Kamijo, K.,
Taketani, S.,
Yokata, S.,
Osumi, T.,
and Hashimoto, T.
(1990)
J. Biol. Chem.
265,
4534-4540 31.
Swinkels, B. W.,
Gould, S. J.,
Bodnar, A. G.,
Rachubinski, R. A.,
and Subramani, S.
(1991)
EMBO J.
10,
3255-3262[Medline]
[Order article via Infotrieve]
32.
Subramani, S.
(1993)
Annu. Rev. Cell Biol.
9,
445-478[CrossRef]
33.
Shoukry, K.,
and Schulz, H.
(1998)
J. Biol. Chem.
273,
6892-6899 34.
Wanders, R. J.,
Jansen, G.,
van Roermund, C. W.,
Denis, S.,
Schutgens, R. B.,
and Jakobs, B. S.
(1996)
Ann. N. Y. Acad. Sci.
804,
450-460[CrossRef][Medline]
[Order article via Infotrieve]
35.
Roe, C. R.,
Millington, D. S.,
Norwood, D. L.,
Kodo, N.,
Sprecher, H.,
Mohammed, B. D.,
Nada, M.,
Schulz, H.,
and McVie, R.
(1990)
J. Clin. Invest.
85,
1703-1707
36.
Kimura, M.,
and Yamaguchi, S.
(1998)
Ryoikibetsu Shokogun Shirizu.
18,
411-413
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. S. Alphey, W. Yu, E. Byres, D. Li, and W. N. Hunter Structure and Reactivity of Human Mitochondrial 2,4-Dienoyl-CoA Reductase: ENZYME-LIGAND INTERACTIONS IN A DISTINCTIVE SHORT-CHAIN REDUCTASE ACTIVE SITE J. Biol. Chem., January 28, 2005; 280(4): 3068 - 3077. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Reumann, C. Ma, S. Lemke, and L. Babujee AraPerox. A Database of Putative Arabidopsis Proteins from Plant Peroxisomes Plant Physiology, September 1, 2004; 136(1): 2587 - 2608. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shechter, P. Dai, L. Huo, and G. Guan IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells J. Lipid Res., November 1, 2003; 44(11): 2169 - 2180. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ferdinandusse, S. Denis, G. Dacremont, and R. J. A. Wanders Studies on the metabolic fate of n-3 polyunsaturated fatty acids J. Lipid Res., October 1, 2003; 44(10): 1992 - 1997. [Abstract] [Full Text] [PDF] |